secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001104659-25-055100
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M
------------------------------------------------------------------------------

- Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.
- Retains right to up to $150M in milestones from Royalty Pharma on 2025/2026 net sales.
- First outcome from Strategic Review Committee formed Nov 2024; board committed to returning excess capital.
- Total potential lifetime value from Trelegy monetization now $1.525B including prior $1.1B upfront.
- 2025 financial guidance unchanged; company continues to focus on YUPELRI and ampreloxetine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/0001104659-25-055100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/tm2516518d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer